CLL patient samples analyzed in Figure 2B-E
| . | IGHV . | Rai at sampling . | Hierarchical cytogenetics . | Therapy . | |||||
|---|---|---|---|---|---|---|---|---|---|
| M-CLL . | U-CLL . | 0 . | I-II . | III-IV . | High risk . | Others . | Treated . | Untreated . | |
| CXCL12 | |||||||||
| % of Control, median (N) | 31 (16) | 26 (11) | 26 (10) | 34 (8) | 34 (9) | 24 (6) | 34 (21) | 32 (13) | 30 (14) |
| P* | <.0001 | .0029 | .002 | .0015 | .0117 | .0014 | <.0001 | .0002 | .0002 |
| CCL19 | |||||||||
| % of Control, median (N) | 34 (16) | 29 (11) | 30 (10) | 40 (8) | 29 (9) | 26 (6) | 33 (21) | 28 (13) | 40 (14) |
| P* | .0042 | .001 | .0488 | .004 | .0117 | .0023 | .0006 | .0012 | .004 |
| BM stroma | |||||||||
| % of Control, median (N) | 32 (4) | 54 (11) | 53 (1) | 67 (6) | 26 (8) | 53 (7) | 46 (8) | 37 (13) | 65 (2) |
| P* | .0365 | .002 | — | .023 | .0148 | .0313 | .0041 | .0005 | — |
| ECM | |||||||||
| % of Control, median (N) | 41 (6) | 45 (4) | 95 (1) | 50 (4) | 35 (5) | 21 (3) | 46 (7) | 36 (6) | 83† (4) |
| P* | .0313 | .0452 | — | .0419 | .0133 | 0.0663 | .0117 | .0313 | 0.2069 |
| . | IGHV . | Rai at sampling . | Hierarchical cytogenetics . | Therapy . | |||||
|---|---|---|---|---|---|---|---|---|---|
| M-CLL . | U-CLL . | 0 . | I-II . | III-IV . | High risk . | Others . | Treated . | Untreated . | |
| CXCL12 | |||||||||
| % of Control, median (N) | 31 (16) | 26 (11) | 26 (10) | 34 (8) | 34 (9) | 24 (6) | 34 (21) | 32 (13) | 30 (14) |
| P* | <.0001 | .0029 | .002 | .0015 | .0117 | .0014 | <.0001 | .0002 | .0002 |
| CCL19 | |||||||||
| % of Control, median (N) | 34 (16) | 29 (11) | 30 (10) | 40 (8) | 29 (9) | 26 (6) | 33 (21) | 28 (13) | 40 (14) |
| P* | .0042 | .001 | .0488 | .004 | .0117 | .0023 | .0006 | .0012 | .004 |
| BM stroma | |||||||||
| % of Control, median (N) | 32 (4) | 54 (11) | 53 (1) | 67 (6) | 26 (8) | 53 (7) | 46 (8) | 37 (13) | 65 (2) |
| P* | .0365 | .002 | — | .023 | .0148 | .0313 | .0041 | .0005 | — |
| ECM | |||||||||
| % of Control, median (N) | 41 (6) | 45 (4) | 95 (1) | 50 (4) | 35 (5) | 21 (3) | 46 (7) | 36 (6) | 83† (4) |
| P* | .0313 | .0452 | — | .0419 | .0133 | 0.0663 | .0117 | .0313 | 0.2069 |
CLL patient samples analyzed in Figure 2B-E were divided into groups based on their clinical and molecular characteristics. Stratification was based on IGHV mutational status (mutated [M-CLL] and unmutated [U-CLL] IGHV); Rai stage at sampling (groups 0/I-II/III-IV; stage II and IV); hierarchical cytogenetics [high risk (del 11q and del 17p) vs others (del 13q, normal karyotype, tris 12)]; and prior therapy (treated vs untreated). For full data, see supplemental Figure 2E-H. Results are summarized for each group in the following format: median percentage of control, number of samples (N), and statistical significance (P). Raw data (migration index [MI] values, supplemental Figure 2A-D) were analyzed by Wilcoxon matched-pairs signed rank test or ratio paired Student t test according to the data distribution. Significant P values are shown in bold.
—, Not applicable.
Control vs CK1 inhibitor treated MI; Wilcoxon matched-pairs signed rank test or ratio paired Student t test according to the data distribution.
Inhibitory effects were significantly different between groups.